L
Description
Tunisian pharmaceutical laboratory founded in 1995 by Dr. Lassaad Boujbel in Nabeul. Produces nearly 200 quality generic medicines. In 2022, launched the first Glargine insulin biosimilar in Tunisia, Africa, and the Arab world. 443 employees, $74.1M revenue.